Li‐Tzong Chen

17.4k total citations · 3 hit papers
296 papers, 7.3k citations indexed

About

Li‐Tzong Chen is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Li‐Tzong Chen has authored 296 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Oncology, 105 papers in Surgery and 84 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Li‐Tzong Chen's work include Pancreatic and Hepatic Oncology Research (76 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers) and Gastric Cancer Management and Outcomes (43 papers). Li‐Tzong Chen is often cited by papers focused on Pancreatic and Hepatic Oncology Research (76 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (47 papers) and Gastric Cancer Management and Outcomes (43 papers). Li‐Tzong Chen collaborates with scholars based in Taiwan, United States and South Korea. Li‐Tzong Chen's co-authors include Yan‐Shen Shan, Ann‐Lii Cheng, Jeffrey S. Chang, Jang‐Yang Chang, Yoon‐Koo Kang, Kun‐Huei Yeh, Nai‐Jung Chiang, Wen‐Chun Hung, Chien‐Feng Li and Chiun Hsu and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Li‐Tzong Chen

287 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Li‐Tzong Chen et al. profile →
Management of gastric cancer in Asia: resource-stratified guidelines

2013 384 citations Yan‐Shen Shan, Kun‐Huei Yeh et al. profile →
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

2022 159 citations Li‐Tzong Chen et al. profile →

Peers

Countries citing papers authored by Li‐Tzong Chen

Since Specialization

Citations

This map shows the geographic impact of Li‐Tzong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li‐Tzong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li‐Tzong Chen more than expected).

Fields of papers citing papers by Li‐Tzong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li‐Tzong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li‐Tzong Chen. The network helps show where Li‐Tzong Chen may publish in the future.

Co-authorship network of co-authors of Li‐Tzong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Li‐Tzong Chen. A scholar is included among the top collaborators of Li‐Tzong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li‐Tzong Chen. Li‐Tzong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study 2025 ·Clinical Cancer Research ·Lin‐Quan Tang, Sai-Lan Liu, Muh‐Hwa Yang, Hui‐Ching Wang, Yujuan Zhou, Kunyu Yang, Qun Li, Mun N. Hui, (unknown), (unknown), Li‐Tzong Chen, (unknown), (unknown), (unknown), Shuang Wang, (unknown), Hanjie Shen, Yu Wang, Ye Guo, Hai‐Qiang Mai	0
2	Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition 2025 ·Clinical and Translational Medicine ·Tzu‐Lei Kuo, Ya‐Chin Hou, Yan‐Shen Shan, Li‐Tzong Chen, Wen‐Chun Hung	0
3	RNF43 Inactivation Enhances the B‐RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells 2024 ·Advanced Science ·(unknown), (unknown), Yeng‐Tseng Wang, Che‐Hung Shen, (unknown), Li‐Tzong Chen, Wen‐Chun Hung	4
4	Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer 2023 ·Cancers ·Yung‐Yeh Su, Nai‐Jung Chiang, Yi‐Hsin Yang, Chia‐Jui Yen, Li‐Yuan Bai, Chang‐Fang Chiu, Shih‐Chang Chuang, Shih‐Hung Yang, Wen‐Chi Chou, Jen‐Shi Chen, Tai‐Jan Chiu, Yen‐Yang Chen, De-Chuan Chan, Cheng‐Ming Peng, (unknown), Chung‐Pin Li, Yan‐Shen Shan, Li‐Tzong Chen	5
5	Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer 2023 ·Biomedicines ·(unknown), Chi‐Wen Luo, (unknown), (unknown), (unknown), (unknown), (unknown), Shih‐Feng Cho, Yi‐Chang Liu, Hui‐Hua Hsiao, Li‐Tzong Chen, Mei‐Ren Pan, Hui‐Ching Wang, Sin‐Hua Moi	2
6	The Prognosis Performance of a Neutrophil- and Lymphocyte-Associated Gene Mutation Score in a Head and Neck Cancer Cohort 2023 ·Biomedicines ·(unknown), Hui‐Ching Wang, Shih‐Feng Cho, Chun‐Chieh Wu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Yi‐Chang Liu, Hui‐Hua Hsiao, Mei‐Ren Pan, Li‐Tzong Chen, Sin‐Hua Moi	1
7	Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness 2022 ·Cancer Science ·(unknown), Li‐Tzong Chen, Horng‐Dar Wang, Yi‐Hong Liu, Shine‐Gwo Shiah	13
8	Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study 2022 ·Clinical Cancer Research ·(unknown), Kien Thiam Tan, Li‐Yuan Bai, Chin‐Fu Hsiao, Chung‐Yu Huang, Yi‐Ping Hung, (unknown), San‐Chi Chen, Yan‐Shen Shan, Yee Chao, Yi‐Hsiang Huang, I‐Cheng Lee, Pei‐Chang Lee, Yung‐Yeh Su, Shu‐Jen Chen, Chun‐Nan Yeh, Li‐Tzong Chen, Ming‐Huang Chen	13
9	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma 2022 ·Cancers ·Sung‐Hsin Kuo, Kun‐Huei Yeh, Chung‐Wu Lin, Jyh‐Ming Liou, Ming‐Shiang Wu, Li‐Tzong Chen, Ann‐Lii Cheng	13
10	An Adjustable Dark-Field Acoustic-Resolution Photoacoustic Imaging System with Fiber Bundle-Based Illumination 2021 ·Biosensors ·(unknown), (unknown), (unknown), (unknown), Chia‐Hua Tsai, (unknown), Tzong-Rong Ger, Li‐Tzong Chen, Wun‐Shaing Wayne Chang, Lun‐De Liao	5
11	Cancer Registry Information Extraction via Transfer Learning 2020 ·(unknown), Hong-Jie Dai, (unknown), (unknown), Yu‐Cheng Chang, (unknown), Chih–Jen Huang, (unknown), Hui‐Min Hsieh, K. S. Clifford Chao, Tsang‐Wu Liu, I‐Shou Chang, Yi‐Hsin Yang, (unknown), Ko‐Jiunn Liu, Li‐Tzong Chen, Sheau‐Fang Yang	0
12	Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib 2017 ·Clinical Cancer Research ·Chien‐Feng Li, Fu‐Min Fang, Yen‐Yang Chen, Tingting Liu, Ti‐Chun Chan, (unknown), Li‐Tzong Chen, Hsuan‐Ying Huang	33
13	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma 2017 ·Scientific Reports ·Sung‐Hsin Kuo, Kun‐Huei Yeh, Ming‐Shiang Wu, Chung‐Wu Lin, Ming‐Feng Wei, Jyh‐Ming Liou, Hsiu‐Po Wang, Li‐Tzong Chen, Ann‐Lii Cheng	19
14	BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT –Driven Myeloid Leukemia 2016 ·Molecular Cancer Therapeutics ·Li‐Tzong Chen, Chiung-Tong Chen, (unknown), Tsai‐Yun Chen, Joseph H. Butterfield, Neng-Yao Shih, John Hsu, (unknown), Sheng-Fung Lin, Hui‐Jen Tsai	10
15	Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL 2016 ·Blood ·Sung‐Hsin Kuo, Li‐Tzong Chen, Chung‐Wu Lin, Kun‐Huei Yeh, Chia‐Tung Shun, (unknown), Jyh‐Ming Liou, Ming‐Shiang Wu, Ping‐Ning Hsu, Ann‐Lii Cheng	20
16	ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance 2013 ·Clinical Cancer Research ·Hsuan-Ying Huang, Wen-Ren Wu, Yu-Hui Wang, Junwen Wang, Fu-Min Fang, Jen-Wei Tsai, Shau-Hsuan Li, (unknown), Shih-Chen Yu, Jui Lan, Yow-Ling Shiue, (unknown), Li‐Tzong Chen, Chien‐Feng Li	118
17	Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma 2013 ·Tumor Biology ·Khin Than Win, Sung-Wei Lee, Hsuan-Ying Huang, Li-Ching Lin, Ching-Yih Lin, Chung‐Hsi Hsing, Li‐Tzong Chen, Chien‐Feng Li	34
18	RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric Cancer Cells by Suppressing ADAM‐Mediated Notch1 Activation 2013 ·Journal of Cellular Physiology ·(unknown), Deng‐Chyang Wu, Kuang‐Hung Cheng, Li‐Tzong Chen, Wen‐Chun Hung	56
19	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas 2012 ·Blood ·Sung‐Hsin Kuo, Kun‐Huei Yeh, Ming‐Shiang Wu, Chung‐Wu Lin, Ping‐Ning Hsu, Hsiu-Po Wang, Li‐Tzong Chen, Ann‐Lii Cheng	95
20	Establishment of a novel MALT lymphoma cell line, ma‐1, from a patient with t(14;18)(q32;q21)‐positive Helicobacter Pylori‐Independent Gastric MALT Lymphoma 2011 ·Genes Chromosomes and Cancer ·Sung‐Hsin Kuo, Wen‐Hui Weng, (unknown), Ping‐Ning Hsu, Ming‐Shiang Wu, Chung‐Wu Lin, (unknown), Kun‐Huei Yeh, Hui‐Jen Tsai, Li‐Tzong Chen, Ann‐Lii Cheng	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact